Evoke Pharma Number of Employees 2012-2025 | EVOK
Evoke Pharma number of employees from 2012 to 2025. Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis
| Evoke Pharma Annual Employee Count | |
|---|---|
| 2024 | 3 |
| 2023 | 4 |
| 2022 | 4 |
| 2021 | 4 |
| 2020 | 5 |
| 2019 | 5 |
| 2018 | 6 |
| 2017 | 7 |
| 2016 | 7 |
| 2015 | 7 |
| 2014 | 7 |
| 2013 | 7 |
| 2012 | 2 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.019B | $0.010B |
| Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| BridgeBio Pharma (BBIO) | United States | $13.352B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $9.749B | 24.85 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.409B | 20.18 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Personalis (PSNL) | United States | $1.687B | 0.00 |
| Taysha Gene Therapies (TSHA) | United States | $1.652B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.019B | 9.58 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |